Immunotherapy has been disappointing as treatment for prostate cancer, but a new Columbia trial suggests it has potential for treating metastatic disease.
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
When all evidence of cancer disappeared from Catherine Spina’s patient after radiation of a single metastasis, she became convinced that radiotherapy may be key to a new treatment approach.
After skin cancer, prostate cancer is the most common cancer diagnosed among men in the United States, and about one in eight men will be diagnosed with the disease during their lifetime.
Columbia researchers have identified a gene signature in localized prostate cancer that predicts the cancer’s odds of spreading and its response to a common treatment for advanced disease.
Leaders in prostate cancer research and care will convene Sept. 22 for the inaugural NYC Prostate Cancer Summit, a patient-focused event co-hosted by CUIMC and NewYork-Presbyterian.
Researchers discovered a mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy.
An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA levels who had more aggressive disease.
Utilizing the latest techniques in molecular biology and genetics, the married team of Cory Abate-Shen and Michael Shen are tackling metastatic prostate cancer.
A study from Columbia University’s Mailman School of Public Health is one of the first assessments of the link between obesity and precancerous abnormalities in biopsy tissue samples.